Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension

Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a severe disease characterised by increased pulmonary vascular resistance, which leads to restricted pulmonary arterial blood flow and elevated pulmonary arterial pressure. In patients with PAH, pulmonary concentrations of prostacyclin, a prostanoid that targ...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Irene M. Lang, Sean P. Gaine
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	European Respiratory Society 2015-12-01
Sraith:	European Respiratory Review
Rochtain ar líne:	http://err.ersjournals.com/content/24/138/630.full

Míreanna comhchosúla

“Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.” Irene M. Lang and Sean P. Gaine. Eur Respir Rev 2015; 24: 630–641.
Foilsithe / Cruthaithe: (2016-03-01)

“Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.” Irene M. Lang, Sean P. Gaine. Eur Respir Rev 2015; 24: 630–641.
Foilsithe / Cruthaithe: (2017-01-01)

Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension
de réir: Stephen J. Halliday, et al.
Foilsithe / Cruthaithe: (2018-09-01)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
de réir: Abdullah A. Alqarni, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Beyond a single pathway: combination therapy in pulmonary arterial hypertension
de réir: Olivier Sitbon, et al.
Foilsithe / Cruthaithe: (2016-12-01)

Transitions between infused and oral prostacyclin pathway agents in pulmonary arterial hypertension: key considerations
de réir: Therese Sargent, et al.
Foilsithe / Cruthaithe: (2020-06-01)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
de réir: Mizuki Momoi, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Prostacyclin-analog therapy in sickle cell pulmonary hypertension
de réir: Nargues A. Weir, et al.
Foilsithe / Cruthaithe: (2017-05-01)

Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension
de réir: Davies EW, et al.
Foilsithe / Cruthaithe: (2018-06-01)

Direct prostacyclin transition in pediatric patients with pulmonary hypertension
de réir: Kelly Merrill, et al.
Foilsithe / Cruthaithe: (2024-04-01)

Challenges in the diagnosis and treatment of pulmonary arterial hypertension
de réir: Jean-Luc Vachiéry, et al.
Foilsithe / Cruthaithe: (2012-12-01)

Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis
de réir: Pengwei Wang, et al.
Foilsithe / Cruthaithe: (2022-02-01)

Paracrine effects of bone marrow-derived endothelial progenitor cells: cyclooxygenase-2/prostacyclin pathway in pulmonary arterial hypertension.
de réir: Dong-Mei Jiang, et al.
Foilsithe / Cruthaithe: (2013-01-01)

Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
de réir: M. Delcroix, et al.
Foilsithe / Cruthaithe: (2009-12-01)

Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis
de réir: Stephen A. Hart, et al.
Foilsithe / Cruthaithe: (2018-02-01)

Pulmonary arterial hypertension: tailoring treatment to risk in the current era
de réir: Sean Gaine, et al.
Foilsithe / Cruthaithe: (2017-12-01)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
de réir: Muhammad Abu‐Rmaileh, et al.
Foilsithe / Cruthaithe: (2023-04-01)

Severe pulmonary hypertension–interstitial lung disease presenting as right ventricular failure: stabilisation with intravenous prostacyclin and maintenance with inhaled prostacyclin
de réir: Raj Parikh, et al.
Foilsithe / Cruthaithe: (2024-01-01)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
de réir: Nathan Holthaus, et al.
Foilsithe / Cruthaithe: (2019-08-01)

Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin
de réir: Majdy Idrees, et al.
Foilsithe / Cruthaithe: (2015-01-01)

Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation
de réir: E. A. Rezukhina, et al.
Foilsithe / Cruthaithe: (2023-03-01)

The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension
de réir: Sean Gaine, et al.
Foilsithe / Cruthaithe: (2013-12-01)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
de réir: Elizabeth Colglazier, et al.
Foilsithe / Cruthaithe: (2022-10-01)

Recent Advances in the Treatment of Pulmonary Arterial Hypertension
de réir: Naoyuki Otani, et al.
Foilsithe / Cruthaithe: (2022-10-01)

An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis
de réir: Alexander J. Ainscough, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
de réir: E. A. Rezukhina, et al.
Foilsithe / Cruthaithe: (2021-09-01)

Interim prostacyclin therapy for an isolated disconnected pulmonary artery: a case report
de réir: Grixti Cynthia, et al.
Foilsithe / Cruthaithe: (2010-06-01)

The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels
de réir: Kevin P. Cunningham, et al.
Foilsithe / Cruthaithe: (2021-06-01)

The use of selexipag, a prostacyclin receptor analog, for treatment of severe pulmonary artery hypertension during pregnancy, a case report
de réir: Akram Khan, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
de réir: Bonnie B. Dean, et al.
Foilsithe / Cruthaithe: (2020-03-01)

Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review
de réir: Burger CD, et al.
Foilsithe / Cruthaithe: (2024-05-01)

Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension
de réir: Rachel K. Hopper, et al.
Foilsithe / Cruthaithe: (2018-02-01)

Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis
de réir: John W. McConnell, et al.
Foilsithe / Cruthaithe: (2020-11-01)

Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey
de réir: Anjali Vaidya, et al.
Foilsithe / Cruthaithe: (2024-11-01)

Correction to: Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
de réir: Bonnie B. Dean, et al.
Foilsithe / Cruthaithe: (2020-06-01)

Prostacyclin pathway vasodilators in patients with chronic thromboembolic pulmonary hypertension (CTEPH): A systemic review and meta‐analysis of randomized controlled trials
de réir: Weijun Li, et al.
Foilsithe / Cruthaithe: (2024-10-01)

Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation
de réir: Aleksander Siniarski, et al.
Foilsithe / Cruthaithe: (2022-10-01)

Platelets, extracellular vesicles and coagulation in pulmonary arterial hypertension
de réir: Sarah Cullivan, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Recent trends in pulmonary arterial hypertension
de réir: Rajagopalan Natarajan
Foilsithe / Cruthaithe: (2011-01-01)

Prostacyclin Synthesis and Prostacyclin Receptor Expression in the Porcine Myometrium: Prostacyclin Potential to Regulate Fatty Acid Transporters, Cytokines and Contractility-Related Factors
de réir: Agnieszka Blitek, et al.
Foilsithe / Cruthaithe: (2022-08-01)